17 pending office actions • 4 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Iovance Biotherapeutics, Inc. | 14 |
| Iovance Biotherapeutics, Inc. | 1 |
| Cellectis SA | 1 |
| Iovance Biotherapeutics, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19033297 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. | NGUYEN, HIEP VAN | 3686 | Non-Final OA | Jan 21, 2025 |
| 18590860 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. | HUYNH, EMILY | 3683 | Final Rejection | Feb 28, 2024 |
| 18580107 | METHOD FOR CRYOPRESERVATION OF SOLID TUMOR FRAGMENTS | Iovance Biotherapeutics, Inc. | BARRON, SEAN C | 1653 | Non-Final OA | Jan 17, 2024 |
| 18551586 | CISH GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | Cellectis SA | RIGA, MICHAEL ANGELO | 1634 | Non-Final OA | Sep 20, 2023 |
| 18262843 | ADJUVANT THERAPY FOR CANCER | Iovance Biotherapeutics, Inc. | WEN, SHARON X | 1641 | Non-Final OA | Jul 25, 2023 |
| 18262365 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | Iovance Biotherapeutics, Inc. | CHASE, CAROL ANN | 1646 | Non-Final OA | Jul 20, 2023 |
| 18256853 | TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | Iovance Biotherapeutics, Inc. | CUNNINGCHEN, KATHLEEN MARY | 1646 | Non-Final OA | Jun 09, 2023 |
| 18249380 | CELL CULTURE SYSTEM AND METHODS OF USING THE SAME | Iovance Biotherapeutics, Inc. | HURST, JONATHAN M | 1799 | Non-Final OA | Apr 17, 2023 |
| 18247878 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | Iovance Biotherapeutics, Inc. | AEDER, SEAN E | 1642 | Non-Final OA | Apr 04, 2023 |
| 17997731 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. | ZHU, JIANJIAN | 1631 | Non-Final OA | Nov 01, 2022 |
| 17997648 | SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS | Iovance Biotherapeutics, Inc. | RAHMAN, MASUDUR | 1633 | Final Rejection | Oct 31, 2022 |
| 17829087 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. | KELLY, ROBERT M | 1638 | Final Rejection | May 31, 2022 |
| 17771723 | GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. | BERTOGLIO, VALARIE E | 1632 | Final Rejection | Apr 25, 2022 |
| 17267699 | Expansion of TILs from Cryopreserved Tumor Samples | Iovance Biotherapeutics, Inc. | O'NEILL, MARISOL ANN | 1633 | Final Rejection | Jan 10, 2022 |
| 17440639 | SEQUENTIAL HETEROLOGOUS BOOST ONCOLYTIC VIRAL IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. | GILL, RACHEL B | 1671 | Non-Final OA | Sep 17, 2021 |
| 17440671 | METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST NEOANTIGENS | Iovance Biotherapeutics, Inc. | SALVOZA, M FRANCO G | 1672 | Final Rejection | Sep 17, 2021 |
| 17415175 | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof | Iovance Biotherapeutics, Inc. | KOLKER, DANIEL E | 1645 | Non-Final OA | Jun 17, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial